Bailard, Inc. Bluebird Bio, Inc. Transaction History

Bailard, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$8.96 - $16.31 $100,352 - $182,672	-11,200 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$11.24 - $21.0 $15,736 - $29,400	1,400 Added 14.29%	11,200 $214,000
Q2 2021 Aug 13, 2021	BUY	$18.04 - $22.09 $176,792 - $216,482	9,800 New	9,800 $313,000
Q4 2020 Feb 03, 2021	SELL	$27.5 - $37.92 $167,750 - $231,312	-6,100 Closed	0 $0
Q4 2019 Jan 31, 2020	BUY	$46.96 - $61.67 $286,456 - $376,187	6,100 New	6,100 $535,000
Q3 2019 Oct 18, 2019	SELL	$59.47 - $93.1 $118,940 - $186,200	-2,000 Closed	0 $0
Q1 2019 Apr 24, 2019	BUY	$64.44 - $104.11 $128,880 - $208,220	2,000 New	2,000 $315,000
Q4 2018 Feb 05, 2019	SELL	$59.1 - $93.26 $118,200 - $186,520	-2,000 Closed	0 $0
Q1 2018 May 07, 2018	SELL	$105.8 - $150.94 $52,900 - $75,470	-500 Reduced 20.0%	2,000 $342,000
Q4 2017 Feb 08, 2018	SELL	$81.25 - $130.7 $203,125 - $326,750	-2,500 Reduced 50.0%	2,500 $0
Q4 2015 Jan 29, 2018	BUY	N/A	5,000	5,000 $0

141

63.2M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $610M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.